Cargando…
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557563/ https://www.ncbi.nlm.nih.gov/pubmed/28810879 http://dx.doi.org/10.1186/s12967-017-1276-7 |
_version_ | 1783257231866724352 |
---|---|
author | Wang, Hui Barbieri, Christopher E. He, Jintang Gao, Yuqian Shi, Tujin Wu, Chaochao Schepmoes, Athena A. Fillmore, Thomas L. Chae, Sung-Suk Huang, Dennis Mosquera, Juan Miguel Qian, Wei-Jun Smith, Richard D. Srivastava, Sudhir Kagan, Jacob Camp, David G. Rodland, Karin D. Rubin, Mark A. Liu, Tao |
author_facet | Wang, Hui Barbieri, Christopher E. He, Jintang Gao, Yuqian Shi, Tujin Wu, Chaochao Schepmoes, Athena A. Fillmore, Thomas L. Chae, Sung-Suk Huang, Dennis Mosquera, Juan Miguel Qian, Wei-Jun Smith, Richard D. Srivastava, Sudhir Kagan, Jacob Camp, David G. Rodland, Karin D. Rubin, Mark A. Liu, Tao |
author_sort | Wang, Hui |
collection | PubMed |
description | BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations. METHODS: To address this issue, PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantifying wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations. RESULTS: Despite inherent limitations due to amino acid sequence constraints, all the PRISM-SRM assays developed using Arg-C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification ranged from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell lines. Expression of the F133V mutation and wild-type SPOP was at much lower levels compared to that of F102C and Y87N mutations; however, at present, it is unknown if this also affects the biological activity of the SPOP protein. CONCLUSIONS: In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, providing significant potential in biomarker development for prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1276-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5557563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55575632017-08-16 Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics Wang, Hui Barbieri, Christopher E. He, Jintang Gao, Yuqian Shi, Tujin Wu, Chaochao Schepmoes, Athena A. Fillmore, Thomas L. Chae, Sung-Suk Huang, Dennis Mosquera, Juan Miguel Qian, Wei-Jun Smith, Richard D. Srivastava, Sudhir Kagan, Jacob Camp, David G. Rodland, Karin D. Rubin, Mark A. Liu, Tao J Transl Med Research BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations. METHODS: To address this issue, PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantifying wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations. RESULTS: Despite inherent limitations due to amino acid sequence constraints, all the PRISM-SRM assays developed using Arg-C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification ranged from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell lines. Expression of the F133V mutation and wild-type SPOP was at much lower levels compared to that of F102C and Y87N mutations; however, at present, it is unknown if this also affects the biological activity of the SPOP protein. CONCLUSIONS: In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, providing significant potential in biomarker development for prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1276-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-15 /pmc/articles/PMC5557563/ /pubmed/28810879 http://dx.doi.org/10.1186/s12967-017-1276-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wang, Hui Barbieri, Christopher E. He, Jintang Gao, Yuqian Shi, Tujin Wu, Chaochao Schepmoes, Athena A. Fillmore, Thomas L. Chae, Sung-Suk Huang, Dennis Mosquera, Juan Miguel Qian, Wei-Jun Smith, Richard D. Srivastava, Sudhir Kagan, Jacob Camp, David G. Rodland, Karin D. Rubin, Mark A. Liu, Tao Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title_full | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title_fullStr | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title_full_unstemmed | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title_short | Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics |
title_sort | quantification of mutant spop proteins in prostate cancer using mass spectrometry-based targeted proteomics |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557563/ https://www.ncbi.nlm.nih.gov/pubmed/28810879 http://dx.doi.org/10.1186/s12967-017-1276-7 |
work_keys_str_mv | AT wanghui quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT barbierichristophere quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT hejintang quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT gaoyuqian quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT shitujin quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT wuchaochao quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT schepmoesathenaa quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT fillmorethomasl quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT chaesungsuk quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT huangdennis quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT mosquerajuanmiguel quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT qianweijun quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT smithrichardd quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT srivastavasudhir quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT kaganjacob quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT campdavidg quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT rodlandkarind quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT rubinmarka quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics AT liutao quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics |